CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 50 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,474,836 | +106.2% | 588,378 | +25.0% | 0.01% | +120.0% |
| Q2 2023 | $8,475,606 | +26.7% | 470,736 | +13.1% | 0.01% | +25.0% |
| Q1 2023 | $6,687,087 | -10.0% | 416,252 | +2.5% | 0.00% | -20.0% |
| Q4 2022 | $7,428,542 | +98.9% | 406,264 | +7.0% | 0.01% | +66.7% |
| Q3 2022 | $3,735,732 | -48.3% | 379,696 | -22.8% | 0.00% | -40.0% |
| Q1 2020 | $7,228,000 | -41.1% | 491,691 | +0.6% | 0.01% | -16.7% |
| Q4 2019 | $12,266,000 | +64.2% | 488,872 | -1.6% | 0.01% | +50.0% |
| Q3 2019 | $7,470,000 | -40.2% | 496,660 | -0.6% | 0.00% | -42.9% |
| Q2 2019 | $12,489,000 | +12.4% | 499,542 | +2.3% | 0.01% | +16.7% |
| Q1 2019 | $11,115,000 | -30.0% | 488,367 | -7.8% | 0.01% | -40.0% |
| Q4 2018 | $15,889,000 | +5.7% | 529,826 | +1.0% | 0.01% | +25.0% |
| Q3 2018 | $15,034,000 | – | 524,744 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |